Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Q3 2025 value amounting to $21336.0.

  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) rose 84.61% to $21336.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $21336.0, marking a year-over-year increase of 84.61%. This contributed to the annual value of $21336.0 for FY2025, which is 84.61% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $21336.0 for Q3 2025, which was up 84.61% from $21.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $21.4 million for Q2 2025, and its period low was $20171.0 during Q3 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $20.8 million (2022), whereas its average is $14.8 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) soared by 235.51% in 2023 and then skyrocketed by 59.85% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $20.4 million in 2021, then grew by 2.1% to $20.8 million in 2022, then rose by 1.31% to $21.1 million in 2023, then increased by 0.71% to $21.2 million in 2024, then plummeted by 99.9% to $21336.0 in 2025.
  • Its last three reported values are $21336.0 in Q3 2025, $21.4 million for Q2 2025, and $21.4 million during Q1 2025.